-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The TIGIT target is becoming the next "sweet pastry" to go overseas
.
On the evening of January 10, 2022, Junshi Bio announced that it has expanded the scope of cooperation with Coherus, and Coherus has launched the licensing option of JS006 (TIGIT monoclonal antibody) in the United States and Canada
The TIGIT target is becoming the next "sweet pastry" to go overseas
01.
Wang Lai, head of BeiGene’s research and development , has the most hope in BeiGene’s pipeline is the TIGIT target
02.
Roche and Merck are the top players in the combination of PD-(L)1+TIGIT
03.
In addition, as the licensor, Innovent also has another TIGIT monoclonal antibody currently in Phase 1 clinical trials
04.
Their next choice is to "buy", which is the answer that the E-pharmaceutical manager got from several companies that have TIGIT in research but no PD-1 research
.
They are optimistic about the combination potential of TIGIT, and PD-1 is now readily available
.